@article{6d5082d8e105497c8a1e06ef3ff69a05,
title = "Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia",
abstract = "Imbalance in neural excitation and inhibition is associated with behavioral dysfunction in individuals with schizophrenia and at risk for this illness. We examined whether targeting increased neural activity with the antiepileptic agent, levetiracetam, would benefit memory performance in a preclinical model of schizophrenia that has been shown to exhibit hyperactivity in the hippocampus. Adult rats exposed to ketamine subchronically during late adolescence showed impaired hippocampal-dependent memory performance. Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats. In contrast, the antipsychotic medication risperidone was not effective in this assessment. Levetiracetam remained effective when administered concurrently with risperidone, supporting potential viability of adjunctive therapy with levetiracetam to treat cognitive deficits in schizophrenia patients under concurrent antipsychotic therapy. In addition to its pro-cognitive effect, levetiracetam was also effective in attenuating amphetamine-induced augmentation of locomotor activity, compatible with the need for therapeutic treatment of positive symptoms in schizophrenia.",
keywords = "Amphetamine, Overactivity, Radial arm maze, Risperidone, SV2A",
author = "Koh, {Ming Teng} and Yi Shao and Sharon Rosenzweig-Lipson and Michela Gallagher",
note = "Funding Information: This research was supported by the Silvo O. Conte Center , P50MH094268 . YS was a Woodrow Wilson Fellow at Johns Hopkins University. Funding Information: MG is the founder of AgeneBio Incorporated, a biotechnology company that is dedicated to discovery and development of therapies to treat cognitive impairment in aging. She has a financial interest in the company. Her conflict of interest is managed by Johns Hopkins University. MTK and MG are inventors on Johns Hopkins University intellectual property licensed to AgeneBio. MTK and YS have received no financial support or compensation from any individual or corporate entity for research or professional services, and have no financial holdings that could be perceived as constituting a potential conflict of interest. SRL is a consultant to AgeneBio and serves as the Vice President of Research. SRL is a former employee of Pfizer and retains Pfizer stock, and has no additional financial holdings that could be perceived as constituting a potential conflict of interest. Funding Information: This research was supported by the Silvo O. Conte Center, P50MH094268. YS was a Woodrow Wilson Fellow at Johns Hopkins University. Publisher Copyright: {\textcopyright} 2017 Elsevier B.V.",
year = "2018",
month = mar,
doi = "10.1016/j.schres.2017.06.027",
language = "English (US)",
volume = "193",
pages = "119--125",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
}